<DOC>
	<DOCNO>NCT02954588</DOCNO>
	<brief_summary>A grow body evidence demonstrate increase adipose mass , especially visceral adipose tissue , contribute directly towards increase systemic inflammation , ( micro- ) vascular dysfunction burden cardiovascular disease ( CVD ) , insulin resistance type 2 diabetes . Advanced glycation/lipoxidation endproducts ( AGEs/ALEs ) heterogeneous family unavoidable by-product , form reactive metabolic intermediate derive glucose lipid oxidation . In addition overwhelming amount data demonstrate role AGEs/ALEs development ( micro- ) vascular dysfunction disease , accumulation AGEs/ALEs expand adipose tissue contribute dysregulation adipokines development insulin resistance . The investigator want examine , double-blind randomize placebo control parallel study , physiological effect dietary intervention pyridoxamine abdominally obese person .</brief_summary>
	<brief_title>Effect Pyridoxamine Supplementation Vascular Function Insulin Sensitivity</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Obesity , Abdominal</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Pyridoxamine</mesh_term>
	<criteria>Abdominal obesity : Waist circumference men 102 cm 120 cm , woman 88 cm 106 cm . Caucasian ( skin fluorescence capillary microscopy measurement ) Aged 1865 year Diabetes ( i.e . use antidiabetic medication , fast glucose &gt; 7.0 mmol/L , HbA1c &gt; 6.5 % ) . Active history cardiovascular disease ( e.g . stroke , coronary artery disease , peripheral vascular disease , congestive heart failure , cardiac shunt , cardiac surgery , pulmonary hypertension , cardiac arrhythmia , family history cardiac arrhythmia sudden cardiac death ) Hyperlipidemia ( define serum total cholesterol &gt; 8 mmol/L TG &gt; 4 mmol/L ) Smoking ( active cessation &lt; 1 year prior screen date ) High alcohol usage ( &gt; 4 U/day ) drug abuse Lipid lower medication ( e.g . statin ) Use medication know influence glucose metabolism , vascular function and/or lipid metabolism ( e.g . statin , glucocorticosteroids , NSAID 's ) Inability stop antihypertensive medication 13 week . Exclusion high grade hypertension ( &gt; 179 mmHg SBP and/or &gt; 109 mmHg DBP ) order expose subject unnecessary risk ) Known allergic reaction ultrasound contrastagent Pulmonary inflammatory disease Kidney failure electrolyte disorder Use dietary supplement investigational product within previous month Unstable body weight ( drastic change life style intervention allow , mean weight gain loss &gt; 3 kg last two month ) Pregnancy lactation No change use oral anticonceptiva IUD ( 12 week prior intervention ) Unwillingness give blood donor ( donate blood ) 8 week prior start study study Insufficient knowledge Dutch language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>